gutflix
GI learning, personalised

Summary

HIGH IL12 AND TH1-RESTRICTED IL23 RECEPTOR EXPRESSION IN THE INTESTINAL LAMINA PROPRIA CELLS IDENTIFIES CROHN'S DISEASE PATIENT'S RESPONDER TO USTEKINUMAB

Sara Onali

UEG Week Copenhagen 2023 | Poster

IBD

October 17, 2023

In this 12-patient prospective study, higher baseline expression of IL12 cytokine subunits and Th1-restricted IL23 receptor in lamina propria was associated with clinical remission at 16 weeks in Crohn's disease patients treated with ustekinumab.

KEY POINTS

- At week 16, 50% (6/12) of CD patients achieved clinical remission (HBI <5) following ustekinumab treatment.
- Patients who achieved remission had significantly higher baseline expression of IL12 cytokine subunits p40 and p35 compared to non-remitters (p=0.001 for both).
- IL23 receptor expression in Th1 cells was significantly higher in remitters (18.0%) compared to non-remitters (5.8%; p=0.009), while expression in other cell types showed no difference between groups.
- No statistically significant difference was found in overall IL12 and IL23 receptor RNA expression between remitters and non-remitters.
- This single-center study enrolled CD patients with active luminal disease who had substantial prior anti-TNF exposure (45.4% IFX, 63.6% ADA) and long disease duration (mean 18.9 years).

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/ed1cb78e-743c-11ee-96ba-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.